Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia

被引:17
作者
Clark, RE
Grzybowski, J
Broughton, CM
Pender, NT
Spiller, DG
Brammer, CG
Giles, RV
Tidd, DM
机构
[1] Royal Liverpool Univ Hosp, Dept Haematol, Liverpool L7 8XP, Merseyside, England
[2] Univ Liverpool, Sch Biol Sci, Liverpool L69 3BX, Merseyside, England
关键词
chronic myeloid leukaemia; blood and marrow transplantation; streptolysin-O; antisense oligodeoxyribonucleotides; BCR-ABL;
D O I
10.1038/sj.bmt.1701801
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Antisense oligodeoxyribonucleotides (ODN) targeted against the breakpoint in BCR-ABL mRNA will specifically decrease BCR-ABL mRNA, provided cells are first permeabilised with streptolysin-O (SL-O), We used 18-mer chimeric methylphosphonodiester: phosphodiester linked (4-9-4) ODN complementary to 9 bases either side of the BCR-ABL junction to purge harvests ex vivo in three CML patients who remained completely Ph positive after multiple chemotherapy courses. After CD34(+) cell selection and SL-O permeabilisation, harvests were purged,vith 20 mu M ODN, After purging, all individual CFU-GM colonies grown from the two b3a2 breakpoint cases remained positive for BCR-ABL mRNA, In contrast, all 24 colonies grown from the b2a2 breakpoint case were BCR-ABL mRNA negative. Patients were conditioned with busulphan 16 mg/kg. The initial post-transplant course was uneventful, although the time to return to 0.5 x 10(9)/l neutrophils was slow at 25-51 days. Both chronic phase patients remain in haematological remission at +724 and +610 days, although each has cytogenetic evidence of relapse. The b2a2 accelerated phase patient died of myeloid blast transformation at day +91, The present SL-O-facilitated ODN purging strategy appears to be without significant toxicity, and offers considerable improvements in ODN delivery to the cytosol.
引用
收藏
页码:1303 / 1308
页数:6
相关论文
共 24 条
[1]  
BEDI A, 1993, BLOOD, V81, P2898
[2]   Autologous transplantation therapy for chronic myelogenous leukemia [J].
Bhatia, R ;
Verfaillie, CM ;
Miller, JS ;
McGlave, PB .
BLOOD, 1997, 89 (08) :2623-2634
[3]   Preclinical studies of streptolysin-O in enhancing antisense oligonucleotide uptake in harvests from chronic myeloid leukaemia patients [J].
Broughton, CM ;
Spiller, DG ;
Pender, N ;
Komorovskaya, M ;
Grzybowski, J ;
Giles, RV ;
Tidd, DM ;
Clark, RE .
LEUKEMIA, 1997, 11 (09) :1435-1441
[4]  
Broughton CM, 1997, GENE CHROMOSOME CANC, V18, P292, DOI 10.1002/(SICI)1098-2264(199704)18:4<292::AID-GCC7>3.3.CO
[5]  
2-I
[6]  
CARELLA AM, 1995, LEUKEMIA, V9, P365
[7]  
CARELLA AM, 1991, LEUKEMIA, V5, P517
[8]   Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: Mobilization of Philadelphia-negative peripheral blood stem cells [J].
Chalmers, EA ;
Franklin, IM ;
Kelsey, SR ;
Newland, AC ;
Clark, RE ;
Sproul, AN ;
Crotty, G ;
McCann, SR ;
Fielding, A ;
Goldstone, AH ;
Hepplestone, A ;
Watson, W ;
Sharp, RA ;
Tansey, P .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 96 (03) :627-634
[9]   BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase [J].
de Fabritiis, P ;
Petti, MC ;
Montefusco, E ;
De Propris, MS ;
Sala, R ;
Bellucci, R ;
Mancini, M ;
Lisci, A ;
Bonetto, F ;
Geiser, T ;
Calabretta, B ;
Mandelli, F .
BLOOD, 1998, 91 (09) :3156-3162
[10]   GENETIC MARKING SHOWS THAT PH(+) CELLS PRESENT IN AUTOLOGOUS TRANSPLANTS OF CHRONIC MYELOGENOUS LEUKEMIA (CML) CONTRIBUTE TO RELAPSE AFTER AUTOLOGOUS BONE-MARROW IN CML [J].
DEISSEROTH, AB ;
ZU, ZF ;
CLAXTON, D ;
HANANIA, EG ;
FU, SQ ;
ELLERSON, D ;
GOLDBERG, L ;
THOMAS, M ;
JANICEK, K ;
ANDERSON, WF ;
HESTER, J ;
KORBLING, M ;
DURETT, A ;
MOEN, R ;
BERENSON, R ;
HEIMFELD, S ;
HAMER, J ;
CALVERT, L ;
TIBBITS, P ;
TALPAZ, M ;
KANTARJIAN, H ;
CHAMPLIN, R ;
READING, C .
BLOOD, 1994, 83 (10) :3068-3076